New virologic tools for management of chronic hepatitis B and C

Gastroenterology

Volumn 142, Issue 6, 2012, Pages

  Chevaliez, Stéphane ^a,b   Rodriguez, Christophe ^a,b   Pawlotsky, Jean Michel ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

Author keywords

Antigen Quantification; Diagnostic Assay; Next Generation Sequencing; Point of Care Tests; Real Time Polymerase Chain Reaction; Real Time Transcription Mediated Amplification

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; BOCEPREVIR; DNA POLYMERASE; ENTECAVIR; HEPATITIS C ANTIGEN; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; TENOFOVIR; VIRUS DNA; VIRUS RNA;

ANTIVIRAL THERAPY; BIOTECHNOLOGY; BLOOD SAMPLING; CLINICAL DECISION MAKING; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DRIED BLOOD SPOT TESTING; DRUG EFFICACY; ENZYME IMMUNOASSAY; GENE AMPLIFICATION; GENETIC ASSOCIATION; GENOMIC IN SITU HYBRIDIZATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIVER BIOPSY; LIVER CIRRHOSIS; MOLECULAR CLONING; MONOTHERAPY; NEXT GENERATION SEQUENCING; POINT OF CARE TESTING; POLYMERASE CHAIN REACTION; POLYMERIZATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION MEDIATED AMPLIFICATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIROLOGY; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION;

EID: 84860273551     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2012.02.027     Document Type: Article

References (78)

1. S. Chevaliez, M. Bouvier-Alias, R. Brillet Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method Hepatology 46 2007 22 31
2. S. Chevaliez, M. Bouvier-Alias, S. Laperche Performance of version 2.0 of the Cobas AmpliPrep/Cobas TaqMan real-time PCR assay for hepatitis B virus DNA quantification J Clin Microbiol 48 2010 3641 3647
3. S. Chevaliez, M. Bouvier-Alias, J.M. Pawlotsky Performance of the Abbott real-time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification J Clin Microbiol 47 2009 1726 1732
4. P. Paba, L. Fabeni, C.F. Perno Performance evaluation of the Artus hepatitis C virus QS-RGQ assay J Virol Methods 179 2012 77 80
5. V. Thibault, C. Pichoud, C. Mullen Characterization of a new sensitive PCR assay for quantification of viral DNA isolated from patients with hepatitis B virus infections J Clin Microbiol 45 2007 3948 3953
6. S. Chevaliez, M. Bouvier-Alias, L. Castera The Cobas AmpliPrep-Cobas TaqMan real-time polymerase chain reaction assay fails to detect hepatitis C virus RNA in highly viremic genotype 4 clinical samples Hepatology 49 2009 1397 1398
7. S. Chevaliez, J. Fix, A. Soulier Underestimation of hepatitis C virus genotype 4 RNA levels by the CobasAmpliPrep/CobasTaqMan assay Hepatology 50 2009 1681
8. J. Vermehren, G. Colucci, P. Gohl Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity J Clin Microbiol 49 2011 3309 3315
9. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B J Hepatol 50 2009 227 242
10. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
11. M.G. Ghany, D.R. Nelson, D.B. Strader An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Hepatology 54 2011 1433 1444
12. M.G. Ghany, D.B. Strader, D.L. Thomas Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
13. Y.F. Liaw, N. Leung, J.H. Kao Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol Int 2 2008 263 283
14. A.S. Lok, B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
15. E. Lawitz, F. Poordad, J.P. Bronowicki The effect of using lower limit of quantitation (LLQ) vs lower limit of detection (LLD) for the definition of undetectable HCV RNA: data from the RESPOND-2 and SPRINT-2 trials Hepatology 54 2011 442A
16. P.R. Harrington, W. Zeng, L.K. Naeger Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment Hepatology 55 2012 1048 1057
17. M.R. Brunetto, F. Moriconi, F. Bonino Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B Hepatology 49 2009 1141 1150
18. R. Moucari, V. Mackiewicz, O. Lada Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients Hepatology 49 2009 1151 1157
19. K. Wursthorn, M. Jung, A. Riva Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients Hepatology 52 2010 1611 1620
20. H.L. Chan, A. Thompson, M. Martinot-Peignoux Hepatitis B surface antigen quantification: why and how to use it in 2011 A core group report J Hepatol 55 2011 1121 1131
21. M.J. Sonneveld, V. Rijckborst, C.A. Boucher A comparison of two assays for quantification of hepatitis B surface antigen in patients with chronic hepatitis B J Clin Virol 51 2011 175 178
22. K. Wursthorn, J. Jaroszewicz, B.J. Zacher Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum J Clin Virol 50 2011 292 296
23. M. Bouvier-Alias, K. Patel, H. Dahari Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication Hepatology 36 2002 211 218
24. Y. Park, J.H. Lee, B.S. Kim New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification J Clin Microbiol 48 2010 2253 2256
25. S. Hosseini-Moghaddam, E. Iran-Pour, C. Rotstein Hepatitis C core Ag and its clinical applicability: potential advantages and disadvantages for diagnosis and follow-up? Rev Med Virol 2012 In press
26. V. Descamps, A. Op de Beeck, C. Plassart Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients J Clin Microbiol 50 2012 465 468
27. G.A. Moscato, G. Giannelli, B. Grandi Quantitative determination of hepatitis C core antigen in therapy monitoring for chronic hepatitis C Intervirology 54 2010 61 65
28. I. Mederacke, A. Potthoff, D. Meyer-Olson HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis J Clin Virol 53 2012 110 115
29. M. Miedouge, K. Saune, N. Kamar Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients J Clin Virol 48 2010 18 21
30. R.S. Ross, S. Viazov, S. Salloum Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification J Clin Microbiol 48 2010 1161 1168
31. R. Jardi, F. Rodriguez-Frias, M. Buti Usefulness of dried blood samples for quantification and molecular characterization of HBV DNA Hepatology 40 2004 133 139
32. E. Tuaillon, A.M. Mondain, F. Meroueh Dried blood spot for hepatitis C virus serology and molecular testing Hepatology 51 2010 752 758
33. A. Marconi, M. Balestrieri, G. Comastri Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens Clin Microbiol Infect 15 2009 93 97
34. F. Sanger, G.M. Air, B.G. Barrell Nucleotide sequence of bacteriophage phi X174 DNA Nature 265 1977 687 695
35. J.M. Prober, G.L. Trainor, R.J. Dam A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides Science 238 1987 336 341
36. L.M. Smith High-speed DNA sequencing by capillary gel electrophoresis Nature 349 1991 812 813
37. W.Y. Wang, B.J. Barratt, D.G. Clayton Genome-wide association studies: theoretical and practical concerns Nature Rev Genet 6 2005 109 118
38. J. Hardy, A. Singleton Genomewide association studies and human disease N Engl J Med 360 2009 1759 1768
39. C.S. Ku, E.Y. Loy, Y. Pawitan The pursuit of genome-wide association studies: where are we now? J Hum Genet 55 2010 195 206
40. Z. Wang, M. Gerstein, M. Snyder RNA-Seq: a revolutionary tool for transcriptomics Nat Rev Genet 10 2009 57 63
41. M.L. Metzker Sequencing technologies: the next generation Nat Rev Genet 11 2010 31 46
42. S. Bennett Solexa Ltd Pharmacogenomics 5 2004 433 438
43. V. Pandey, R.C. Nutter, E. Prediger Applied biosystems SOLiD system: ligation-based sequencing M. Janits, Next-generation genome sequencing Towards personnalized medicine 2008 Wiley Hoboken, NJ 29 42
44. M. Margulies, M. Egholm, W.E. Altman Genome sequencing in microfabricated high-density picolitre reactors Nature 437 2005 376 380
45. J.M. Rothberg, W. Hinz, T.M. Rearick An integrated semiconductor device enabling non-optical genome sequencing Nature 475 2011 348 352
46. J. Eid, A. Fehr, J. Gray Real-time DNA sequencing from single polymerase molecules Science 323 2009 133 138
47. O. Harismendy, P.C. Ng, R.L. Strausberg Evaluation of next-generation sequencing platforms for population targeted sequencing studies Genome Biol 10 2009 R32
48. Y. Shen, S. Sarin, Y. Liu Comparing platforms for C elegans mutant identification using high-throughput whole-genome sequencing PloS One 3 2008 e4012
49. N.A. Walter, D. Bottomly, T. Laderas High throughput sequencing in mice: a platform comparison identifies a preponderance of cryptic SNPs BMC Genomics 10 2009 379
50. S. Suzuki, N. Ono, C. Furusawa Comparison of sequence reads obtained from three next-generation sequencing platforms PloS One 6 2011 e19534
51. J.C. Dohm, C. Lottaz, T. Borodina Substantial biases in ultra-short read data sets from high-throughput DNA sequencing Nucleic Acids Res 36 2008 e105
52. N. Hoppman-Chaney, L.M. Peterson, E.W. Klee Evaluation of oligonucleotide sequence capture arrays and comparison of next-generation sequencing platforms for use in molecular diagnostics Clin Chem 56 2010 1297 1306
53. A. Gilles, E. Meglecz, N. Pech Accuracy and quality assessment of 454 GS-FLX titanium pyrosequencing BMC Genomics 12 2011 245
54. B. Ewing, P. Green Base-calling of automated sequencer traces using Phred II. Error probabilities Genome Res 8 1998 186 194
55. B. Ewing, L. Hillier, M.C. Wendl Base-calling of automated sequencer traces using Phred I. Accuracy assessment Genome Res 8 1998 175 185
56. P. Richterich Estimation of errors in "raw" DNA sequences: a validation study Genome Res 8 1998 251 259
57. B.G. Richter, D.P. Sexton Managing and analyzing next-generation sequence data PLoS Computat Biol 5 2009 e1000369
58. D. Altshuler, V.J. Pollara, C.R. Cowles An SNP map of the human genome generated by reduced representation shotgun sequencing Nature 407 2000 513 516
59. C. Wang, Y. Mitsuya, B. Gharizadeh Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance Genome Res 17 2007 1195 1201
60. A.M. Tsibris, B. Korber, R. Arnaout Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo PloS One 4 2009 e5683
61. J. Archer, A. Rambaut, B.E. Taillon The evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time-an ultra-deep approach PLoS Comput Biol 6 2010 e1001022
62. A.F. Poon, L.C. Swenson, W.W. Dong Phylogenetic analysis of population-based and deep sequencing data to identify coevolving sites in the nef gene of HIV-1 Molecular Biol Evol 27 2010 819 832
63. S. Gianella, W. Delport, M.E. Pacold Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants J Virol 85 2011 8359 8367
64. C. Rodriguez, C. Chevaliez, P. Bensadoun Ultra-deep pyrosequencing, a powerful new tool to study HBV resistance to nucleoside/nucleotide analogues, identifies pre-existing HBV variants bearing resistance mutations and characterizes their on-treatment kinetics Hepatology 52 2011 117A
65. S. Chevaliez, C. Rodriguez, A. Soulier Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations J Hepatol 54 2011 S30
66. C. Rodriguez, C. Soulie, A. Marcelin HIV-1 coreceptor usage prediction by "ultra-deep pyrosequencing" increases the rate of patients treated with success by CCR5 antagonists Antiviral Ther 16 2011 A100
67. C.F. Chen, W.C. Lee, H.I. Yang Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma Gastroenterology 141 2011 1240 1248
68. C.J. Chen, H.I. Yang, U.H. Iloeje Hepatitis B virus DNA levels and outcomes in chronic hepatitis B Hepatology 49 2009 S72 S84
69. E.H. Buster, H.L. Janssen The importance of HBV genotype in HBeAg-positive chronic hepatitis B patients in whom sustained response is pursued J Hepatol 54 2011 395 396
70. S. Raimondi, P. Maisonneuve, S. Bruno Is response to antiviral treatment influenced by hepatitis B virus genotype? J Hepatol 52 2010 441 449
71. G. Woo, G. Tomlinson, Y. Nishikawa Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses Gastroenterology 139 2010 1218 1229
72. R. Zoutendijk, J.G. Reijnders, A. Brown Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response Hepatology 54 2011 443 451
73. J.M. Pawlotsky, G. Dusheiko, A. Hatzakis Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach Gastroenterology 134 2008 405 415
74. S. Chevaliez, M. Bouvier-Alias, R. Brillet Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice PLoS One 4 2009 e8209
75. P.J. Clark, A.J. Thompson Host genomics and HCV treatment response J Gastroenterol Hepatol 27 2012 212 222
76. J.M. Pawlotsky Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 2011 1742 1751
77. J.C. Sullivan, S. De Meyer, D.J. Bartels Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials J Hepatol 54 2011 S4
78. S. Zeuzem, R.J. Barnard, J.A. Howe Boceprevir resistance-associated variants (RAVS) are observed more frequently in HCV (GT1)-infected patients with poor response to peginterferon α-2b/ribavirin J Hepatol 54 2011 S4 S5